What Are CJC-1295 and Ipamorelin? A Complete Guide to the Growth Hormone Secretagogues

CJC-1295 and ipamorelin are experimental compounds that stimulate the body’s growth-hormone system through different biological pathways.

They are frequently discussed together because:

• CJC-1295 acts through the growth hormone-releasing hormone pathway.

• Ipamorelin acts through the ghrelin receptor.

• Both can stimulate growth hormone release from the pituitary gland.

• Their effects may be additive or synergistic when the pathways are activated together.

Online descriptions commonly claim that the combination can:

• Increase muscle growth

• Reduce body fat

• Improve sleep

• Accelerate recovery

• Strengthen tendons

• Increase energy

• Improve skin quality

• Reverse ageing

Most of these claims go substantially beyond the available clinical evidence.

CJC-1295 has been tested in small controlled human studies and was shown to produce prolonged increases in growth hormone and insulin-like growth factor 1, or IGF-1.

Ipamorelin has also entered human clinical research, but its principal clinical programme investigated gastrointestinal motility and postoperative ileus rather than bodybuilding, fat loss or anti-ageing.

There are no large, high-quality clinical trials establishing the commonly promoted CJC-1295 and ipamorelin combination as an effective treatment for:

• Muscle gain

• Athletic recovery

• Obesity

• Sleep disorders

• Age-related decline

• Tendon or ligament injuries

The substances are not authorised UK medicines for these purposes and are prohibited in regulated sport.

An additional source of confusion is that the name CJC-1295 is used inconsistently.

True CJC-1295 contains a drug affinity complex, commonly abbreviated to DAC, which allows it to bind covalently to circulating albumin and remain active for several days.

Products called “CJC-1295 without DAC” are chemically different short-acting growth hormone-releasing hormone analogues and should not be treated as identical to the original long-acting CJC-1295 molecule.

This guide explains the normal growth-hormone system, how each compound works, what controlled research has demonstrated and which popular claims remain unsupported.

CJC-1295 and ipamorelin quick facts

A controlled human study found that a single dose of long-acting CJC-1295 increased growth hormone for at least six days and raised IGF-1 for approximately nine to eleven days. Repeated exposure maintained increased concentrations without evidence of progressively diminishing responses during the study period.

Understanding the growth-hormone system

Growth hormone is a peptide hormone produced by the anterior pituitary gland.

Its release is controlled through a network involving:

• The hypothalamus

• The pituitary gland

• Growth hormone-releasing hormone

• Somatostatin

• Ghrelin

• Sleep

• Exercise

• Nutrition

• Blood glucose

• Free fatty acids

• Age

• Sex hormones

• Feedback from IGF-1

Growth hormone is secreted in pulses rather than at a constant rate.

The largest natural pulse often occurs during the early part of sleep, particularly around slow-wave sleep.

Additional pulses may occur in response to:

• Exercise

• Fasting

• Hypoglycaemia

• Physiological stress

• Certain amino acids

• Growth hormone-releasing signals

Random growth-hormone blood measurements can therefore be difficult to interpret.

A low result taken between pulses does not necessarily indicate growth-hormone deficiency, while a high result during a pulse does not automatically indicate excess production.

What is growth hormone-releasing hormone?

Growth hormone-releasing hormone, abbreviated to GHRH, is produced in the hypothalamus.

It travels to the pituitary gland and binds to the GHRH receptor on growth-hormone-producing cells known as somatotrophs.

This activates intracellular signalling that promotes:

• Growth hormone synthesis

• Growth hormone release

• Maintenance of pituitary somatotroph function

Natural human GHRH contains 44 amino acids.

Much of its biological activity lies within its first 29 amino acids, which led to the development of shorter synthetic analogues.

Examples of GHRH-related compounds include:

• Sermorelin

• Tesamorelin

• CJC-1295

• Modified GRF 1-29

• CJC-1293

These compounds differ in their:

• Amino-acid sequence

• Resistance to enzyme degradation

• Duration of action

• Albumin binding

• Approved indications

• Clinical evidence

They should not be treated as interchangeable.

What is ghrelin?

Ghrelin is a naturally occurring peptide hormone produced mainly in the stomach.

It was identified as the natural ligand for the growth hormone secretagogue receptor.

Ghrelin can influence:

• Growth hormone release

• Hunger

• Food intake

• Gastric motility

• Glucose regulation

• Reward-related signalling

• Energy balance

Ghrelin requires a specific fatty-acid modification, known as acylation, to activate the classical GHS-R1a receptor effectively.

Its discovery demonstrated that growth hormone can be regulated through a pathway separate from the GHRH receptor.

What is CJC-1295?

CJC-1295 is a synthetic analogue of the active portion of growth hormone-releasing hormone.

It was developed to overcome a major limitation of natural GHRH: rapid breakdown and a very short duration of action.

The original CJC-1295 molecule contains:

• A modified GHRH-derived peptide sequence

• Amino-acid substitutions that increase resistance to enzymatic degradation

• A reactive drug affinity complex

• A maleimide group capable of binding circulating albumin

Albumin is a highly abundant blood protein with a relatively long circulating lifespan.

After administration, CJC-1295’s reactive group forms a covalent bond with albumin.

This creates a circulating peptide-albumin conjugate that remains available to stimulate GHRH receptors for much longer than ordinary GHRH.

Human studies demonstrated prolonged increases in growth hormone and IGF-1 after a single exposure.

What does DAC mean?

DAC stands for drug affinity complex.

It is the chemical feature that allows original CJC-1295 to attach to circulating albumin.

This substantially changes the compound’s pharmacological behaviour.

CJC-1295 with DAC is therefore:

• Long acting

• Albumin bound

• Capable of affecting GH and IGF-1 for several days

• Different from short-acting GHRH analogues

The DAC is not merely a brand name or optional additive.

It is a structural feature that defines the long-acting compound described in the principal CJC-1295 clinical studies.

What is “CJC-1295 without DAC”?

The term “CJC-1295 without DAC” is widely used commercially, but it is scientifically confusing.

A compound without the drug affinity complex cannot form the same long-lasting albumin conjugate as original CJC-1295.

Products marketed under this name are often intended to represent a modified growth hormone-releasing factor commonly called:

• Modified GRF 1-29

• Mod GRF 1-29

• Tetrasubstituted GRF 1-29

This is a short-acting GHRH analogue.

It contains substitutions designed to resist rapid enzymatic breakdown but does not possess the albumin-binding DAC structure.

Therefore:

CJC-1295 with DAC and “CJC-1295 without DAC” are not simply long- and short-lasting versions of an otherwise identical molecule.

They are structurally and pharmacokinetically different compounds.

Why does the distinction matter?

The distinction affects:

• Duration of action

• Growth-hormone exposure

• IGF-1 elevation

• Pulse pattern

• Accumulation

• Detection

• Safety interpretation

• Study relevance

Human studies showing growth-hormone and IGF-1 elevation for several days investigated CJC-1295 with DAC.

Those results should not automatically be applied to modified GRF 1-29.

Likewise, dosing schedules discussed for a short-acting GHRH analogue cannot be assumed to apply to the long-acting albumin-bound compound.

Using the same name for both creates avoidable confusion in research interpretation.

How was CJC-1295 designed?

Natural GHRH is quickly degraded by enzymes, particularly dipeptidyl peptidase-4.

Researchers modified several amino acids within the active GHRH sequence to improve resistance to enzymatic breakdown.

A reactive chemical group was then added to permit albumin binding.

In preclinical research, CJC-1295 generated substantially greater growth-hormone exposure than unmodified GHRH 1-29.

The design aimed to create sustained stimulation without requiring continuous infusion.

What did the main CJC-1295 human study find?

The most frequently cited CJC-1295 study consisted of two randomised, double-blind, placebo-controlled, ascending-dose trials in healthy adults.

Researchers assessed:

• Pharmacokinetics

• Growth-hormone concentrations

• IGF-1 concentrations

• Repeated exposure

• Tolerability

Following a single administration, CJC-1295 produced:

• Dose-dependent increases in mean growth hormone

• Increased IGF-1

• Growth-hormone elevation lasting several days

• IGF-1 elevation lasting longer than the GH increase

• An estimated circulating half-life measured in days rather than minutes

Repeated exposure maintained increased IGF-1 without evidence of tachyphylaxis during the study.

The study established that CJC-1295 is biologically active in humans.

It did not establish long-term benefits for muscle growth, fat loss, recovery or ageing.

Does CJC-1295 preserve growth-hormone pulses?

A separate analysis examined detailed growth-hormone secretion after CJC-1295.

Researchers reported that normal pulsatile secretion remained present.

However, the peptide markedly increased basal or trough growth-hormone levels.

This raised average growth-hormone and IGF-1 exposure even though the frequency and size of individual natural pulses were not substantially changed.

The study reported approximately:

• A 7.5-fold increase in trough growth hormone

• A 46% increase in mean growth hormone

• A 45% increase in IGF-1

These results show that preserved pulsatility does not mean the endocrine system remains completely unchanged.

The baseline between pulses was substantially elevated.

Is CJC-1295 physiological?

CJC-1295 stimulates the body’s own pituitary gland rather than supplying recombinant growth hormone directly.

For that reason, it is sometimes described as more physiological than administering growth hormone.

That description requires qualification.

Although growth hormone still comes from the pituitary:

• The stimulating signal is externally introduced.

• The signal lasts much longer than natural GHRH.

• Basal growth-hormone concentrations can remain elevated.

• IGF-1 can remain increased for many days.

• Normal feedback systems may be exposed to an unnatural stimulus.

Endogenous production does not automatically mean physiological exposure.

What is ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue.

It is a short pentapeptide, meaning that it contains five amino-acid-related units.

Unlike CJC-1295, it does not primarily activate the GHRH receptor.

It acts as an agonist of the growth hormone secretagogue receptor, most commonly called GHS-R1a or the ghrelin receptor.

Activation of this receptor stimulates growth hormone release from the pituitary.

Ipamorelin was developed as a comparatively selective growth hormone secretagogue.

Early animal research found that it stimulated growth hormone while producing less activation of adrenocorticotropic hormone and cortisol than older growth hormone-releasing peptides at the tested exposures.

Is ipamorelin the same as ghrelin?

No.

Ipamorelin activates the same principal receptor but is not structurally identical to ghrelin.

Ghrelin is a naturally occurring acylated peptide with effects involving:

• Hunger

• Food intake

• Reward

• Gastric movement

• Glucose metabolism

• Growth-hormone release

Ipamorelin is a synthetic receptor agonist designed to stimulate selected ghrelin-receptor effects.

Its selectivity is relative rather than absolute.

Activating a receptor involved in multiple physiological systems may produce effects beyond growth-hormone release.

Is ipamorelin a GHRP?

Yes.

Ipamorelin belongs to the group commonly known as growth hormone-releasing peptides or growth hormone secretagogues.

Other compounds in this broad category include:

• GHRP-2

• GHRP-6

• Hexarelin

• Macimorelin

• Alexamorelin

These molecules differ in:

• Receptor potency

• Appetite effects

• Cortisol effects

• Prolactin effects

• Duration

• Oral activity

• Clinical development

• Safety data

Evidence from one growth hormone secretagogue cannot automatically be assigned to another.

How does ipamorelin stimulate growth hormone?

Ipamorelin binds to GHS-R1a receptors in the pituitary and hypothalamic system.

This activates signalling that promotes growth-hormone release.

The mechanism differs from GHRH receptor activation.

The ghrelin receptor also has relatively high baseline activity, meaning that it can signal even without a ligand.

Ghrelin-receptor agonists may influence:

• Pituitary growth-hormone release

• Hypothalamic regulation

• Gastrointestinal movement

• Appetite-related pathways

• Autonomic signalling

• Glucose metabolism

The complete effect depends on the compound, exposure and biological context.

Why are CJC-1295 and ipamorelin combined?

CJC-1295 and ipamorelin stimulate growth hormone through two complementary pathways:

• CJC-1295 activates GHRH receptors.

• Ipamorelin activates ghrelin receptors.

Natural growth-hormone secretion is most powerful when these pathways act together and somatostatin inhibition is reduced.

This creates a plausible basis for a larger growth-hormone response when a GHRH analogue and a ghrelin-receptor agonist are combined.

Research involving other GHRH compounds and growth hormone-releasing peptides has demonstrated synergistic growth-hormone release.

However, this biological principle does not prove that the specific CJC-1295 and ipamorelin combination provides clinically meaningful benefits.

There are no mature controlled trials establishing the combination for body composition, performance, recovery or anti-ageing.

What is synergy?

Synergy occurs when two substances together produce an effect greater than would be expected from simply adding their separate effects.

In growth-hormone physiology:

• GHRH stimulates somatotroph activity through one receptor.

• Ghrelin-receptor agonists stimulate through another pathway.

• Each pathway can amplify the response to the other.

The presence of synergy also creates the possibility of:

• Larger-than-expected hormone exposure

• Higher IGF-1

• Greater adverse effects

• More variability between individuals

Synergy should not automatically be treated as beneficial.

What is IGF-1?

IGF-1 stands for insulin-like growth factor 1.

It is produced mainly by the liver in response to growth hormone, although many tissues produce IGF-1 locally.

IGF-1 contributes to:

• Childhood growth

• Protein synthesis

• Bone metabolism

• Tissue development

• Cell survival

• Glucose metabolism

Blood IGF-1 is often used as a more stable marker of average growth-hormone activity because it fluctuates less dramatically than growth hormone.

However, IGF-1 is not a direct measurement of every growth-hormone effect.

Its concentration is also influenced by:

• Age

• Nutrition

• Liver function

• Insulin

• Thyroid status

• Sex hormones

• Chronic illness

• Kidney function

Does a higher IGF-1 level mean better health?

No.

Very low IGF-1 may reflect growth-hormone deficiency, malnutrition, liver disease or other illness.

Excessively high IGF-1 may indicate growth-hormone excess and is associated with the disease acromegaly when caused by chronic pathological GH secretion.

The physiological relationship is not simply “more is better.”

Appropriate concentrations depend on:

• Age

• Sex

• Laboratory reference range

• Clinical context

• Underlying health

Raising an already normal IGF-1 level has not been proven to produce general anti-ageing benefits.

CJC-1295, ipamorelin and muscle growth

Growth hormone and IGF-1 participate in protein metabolism and tissue growth.

This creates a plausible reason to investigate secretagogues in conditions involving:

• Growth-hormone deficiency

• Muscle wasting

• Frailty

• Severe catabolic illness

However, growth hormone’s effects on muscle are frequently overstated.

In healthy adults, increased growth hormone may increase lean-body-mass measurements partly through:

• Fluid retention

• Connective-tissue growth

• Increased extracellular water

An increase in measured lean mass does not necessarily represent a proportional increase in contractile muscle.

There are no strong controlled trials showing that CJC-1295 and ipamorelin produce substantial functional muscle growth in healthy adults.

Do they increase strength?

No reliable evidence establishes meaningful strength improvements from the combination.

Muscle strength depends on:

• Muscle cross-sectional area

• Neurological adaptation

• Technique

• Tendon stiffness

• Training experience

• Motivation

• Leverage

• Recovery

A rise in growth hormone or IGF-1 does not automatically increase maximal strength.

Controlled trials would need to measure outcomes such as:

• One-repetition maximum

• Isokinetic force

• Grip strength

• Power output

• Functional performance

Those data are not available for the commonly promoted combination.

Do they improve recovery?

Recovery can mean:

• Reduced muscle soreness

• Faster glycogen replacement

• Tendon repair

• Improved sleep

• Reduced fatigue

• Faster healing after surgery

• Return to athletic performance

There are no robust human trials establishing broad recovery benefits from CJC-1295 and ipamorelin.

Growth hormone can influence connective-tissue metabolism, but increased hormonal signalling does not guarantee that an injury heals faster or more completely.

Recovery is also affected by:

• Injury type

• Rehabilitation

• Nutrition

• Training load

• Sleep

• Age

• Blood supply

• Medication

• Metabolic health

Do they heal tendons and ligaments?

There is no controlled evidence that the combination heals human tendon or ligament injuries.

Growth hormone and IGF-1 influence collagen metabolism, which provides a theoretical mechanism.

However, tendon recovery requires:

• Correct diagnosis

• Progressive loading

• Collagen alignment

• Restoration of mechanical strength

• Appropriate movement

• Long-term remodelling

Increasing a growth-related signal does not ensure that new tissue is correctly organised.

Pain improvement should not be interpreted automatically as structural repair.

CJC-1295, ipamorelin and fat loss

Growth hormone can affect fat metabolism by increasing lipolysis, the release of fatty acids from stored fat.

Chronic growth-hormone excess can reduce fat mass in some contexts.

This has led to claims that secretagogues are fat-loss compounds.

Human CJC-1295 studies demonstrated hormonal effects but did not establish substantial weight loss in healthy adults.

A phase 2 trial was registered to investigate CJC-1295 in people with HIV-associated visceral obesity, but the existence of a study does not establish successful treatment, and publicly available evidence has not produced an approved CJC-1295 obesity medicine.

No high-quality evidence shows that the CJC-1295 and ipamorelin combination produces weight loss comparable with authorised obesity treatments.

Does the combination reduce visceral fat?

This remains unproven.

Growth-hormone signalling is involved in visceral-fat regulation, and people with growth-hormone deficiency may have increased abdominal fat.

However, restoring a deficiency is different from increasing growth-hormone activity in a person with normal pituitary function.

Studies would need to use reliable methods such as:

• Magnetic resonance imaging

• Computed tomography

• Dual-energy X-ray absorptiometry

• Standardised waist measurements

Visual changes or scale weight alone cannot establish selective visceral-fat loss.

Can growth-hormone secretagogues increase blood glucose?

Yes, this is biologically plausible.

Growth hormone can oppose some actions of insulin and increase hepatic glucose production.

Sustained growth-hormone or IGF-1 pathway manipulation may affect:

• Fasting glucose

• Insulin sensitivity

• Insulin concentrations

• Glucose tolerance

The direction and magnitude may depend on:

• Baseline insulin sensitivity

• Body composition

• Diet

• Exposure

• Age

• Concurrent medication

• Existing diabetes risk

People often assume that stimulating natural growth hormone avoids metabolic effects associated with recombinant growth hormone.

That assumption has not been established.

Could they cause insulin resistance?

Potentially.

Chronic growth-hormone excess is associated with impaired insulin sensitivity.

Short-term physiological pulses and prolonged elevated baseline growth hormone are not metabolically identical.

The CJC-1295 human study showed that trough growth-hormone concentrations could remain substantially elevated.

Long-term trials would need to assess:

• Fasting glucose

• HbA1c

• Fasting insulin

• Oral glucose tolerance

• Diabetes incidence

• Changes in body composition

The safety of prolonged combination exposure has not been defined adequately.

CJC-1295, ipamorelin and sleep

Growth hormone is naturally linked with sleep, especially slow-wave sleep.

This association has led to claims that increasing growth-hormone secretion improves sleep quality.

The relationship is not that simple.

Growth-hormone release can be a consequence of normal sleep architecture rather than a cause of better sleep.

Studies of other growth hormone-releasing peptides have not consistently shown improved slow-wave sleep even when growth hormone increased.

There are no strong controlled trials demonstrating that the CJC-1295 and ipamorelin combination treats:

• Insomnia

• Sleep apnoea

• Fragmented sleep

• Non-restorative sleep

Sleep apnoea is particularly important because growth-related hormones and fluid retention may potentially worsen upper-airway problems in susceptible individuals.

Does ipamorelin increase appetite?

Ipamorelin activates the ghrelin receptor, which is involved in hunger and food intake.

Older growth hormone-releasing peptides, particularly GHRP-6, are well known for appetite effects.

Ipamorelin was designed to be more selective for growth-hormone release, but that does not prove it has no effect on appetite.

Human appetite data are limited.

The degree of hunger may vary according to:

• Exposure

• Timing

• Individual receptor sensitivity

• Blood glucose

• Meal timing

• Other compounds

Statements that ipamorelin categorically cannot increase appetite are too strong.

Ipamorelin and gastrointestinal motility

Ipamorelin’s most substantial human clinical research involved postoperative ileus.

Postoperative ileus is a temporary reduction in intestinal movement after surgery.

Because ghrelin-receptor agonists can promote gastrointestinal motility, ipamorelin was investigated as a possible treatment.

A phase 2 randomised controlled study examined ipamorelin after bowel surgery.

The compound did not achieve a sufficiently convincing clinical result to become an established treatment for postoperative ileus.

This clinical programme demonstrates that ipamorelin has pharmacological effects beyond bodybuilding-related claims.

It also illustrates that a promising mechanism and positive animal results do not guarantee successful human treatment.

Is ipamorelin selective?

Early preclinical research described ipamorelin as selective for growth-hormone release.

Compared with some older GHRPs, it produced less ACTH and cortisol release in the experimental models studied.

This is the basis for the common claim that ipamorelin does not affect cortisol or prolactin.

However:

• Most foundational selectivity data were preclinical.

• Selectivity can depend on dose.

• Human endocrine responses may vary.

• “Less effect” does not mean “no possible effect.”

• Product identity and exposure may be uncertain outside clinical research.

It is more accurate to say that ipamorelin was developed as a relatively selective growth hormone secretagogue.

Does ipamorelin increase cortisol?

It appears less likely to increase ACTH and cortisol than some older growth hormone-releasing peptides at comparable growth-hormone-stimulating exposures.

That does not establish that cortisol can never change.

Human endocrine studies would need to account for:

• Time of day

• Stress

• Sleep

• Blood sampling

• Exposure

• Concurrent compounds

Cortisol fluctuates substantially under normal conditions, making anecdotal conclusions unreliable.

Does ipamorelin increase prolactin?

Ipamorelin is generally considered less prolactin-stimulating than GHRP-2 or GHRP-6.

However, comprehensive controlled human data are limited.

A normal prolactin result in one person does not prove that the compound has no prolactin-related effect in all users.

Can the combination cause water retention?

Potentially.

Growth hormone and IGF-1 can influence:

• Sodium retention

• Fluid balance

• Soft-tissue volume

Known effects associated with excessive growth-hormone exposure can include:

• Swelling

• Tight rings

• Puffy hands

• Ankle oedema

• Increased body weight

• Joint stiffness

• Tingling

Fluid retention may also make lean-body-mass measurements appear to improve without equivalent contractile-muscle gain.

Can it cause carpal tunnel symptoms?

Potentially.

Growth-hormone-related fluid retention can increase pressure around peripheral nerves.

Symptoms may include:

• Tingling

• Numbness

• Burning

• Hand weakness

• Night-time discomfort

Carpal tunnel symptoms are recognised in settings involving excess growth-hormone exposure.

Their frequency with CJC-1295 and ipamorelin has not been established through large trials.

Can it cause headaches?

Headaches may occur for many reasons, including:

• Hormonal changes

• Blood-pressure changes

• Fluid shifts

• Blood-glucose changes

• Injection-related stress

• An unrelated condition

Headache has been reported in growth-hormone-related clinical research, but the specific incidence with the combination is unknown.

A sudden severe headache, neurological symptoms or visual disturbance requires urgent assessment rather than being assumed to be a routine peptide effect.

Could the combination affect blood pressure?

Potentially.

Growth hormone, IGF-1, fluid balance and ghrelin signalling can all influence cardiovascular physiology.

Possible effects could include changes in:

• Sodium retention

• Blood volume

• Vascular tone

• Heart rate

• Glucose regulation

There is insufficient long-term controlled research to define cardiovascular safety for the combination.

Growth hormone and the heart

Normal growth-hormone signalling is important for cardiovascular health.

Both deficiency and excess can be associated with adverse effects.

Chronic pathological growth-hormone excess, as seen in acromegaly, can contribute to:

• High blood pressure

• Heart enlargement

• Cardiomyopathy

• Arrhythmias

• Sleep apnoea

• Glucose intolerance

The hormonal elevations produced by experimental secretagogues are not identical to acromegaly.

Nevertheless, the disease demonstrates that sustained growth-hormone and IGF-1 excess is not automatically beneficial.

Cancer-related considerations

There is no evidence that CJC-1295 or ipamorelin has been proven to cause cancer in humans.

There is also inadequate evidence to establish long-term safety in people with:

• Active cancer

• Previous cancer

• Undiagnosed tumours

• High inherited cancer risk

Growth hormone and IGF-1 promote cell survival and growth in several tissues.

Cancer biology is complex, and increased IGF-1 does not mean that cancer will inevitably occur.

However, chronic stimulation of growth-related pathways requires careful long-term evaluation.

Small short-duration trials cannot resolve:

• Cancer incidence

• Tumour growth

• Recurrence risk

• Effects in different cancer types

Claims that growth hormone secretagogues are completely safe in relation to cancer are not supported.

Can CJC-1295 enlarge organs?

There is no direct evidence that ordinary experimental exposure reliably produces clinically significant organ enlargement.

However, chronic excessive growth-hormone and IGF-1 signalling can promote soft-tissue and organ growth.

Long-term concerns would include possible effects on:

• The heart

• Kidneys

• Liver

• Thyroid

• Intestinal tissue

These risks cannot be quantified without larger, longer studies.

Can they affect the thyroid?

Growth hormone can alter thyroid-hormone metabolism.

In some contexts it can increase conversion of thyroxine, or T4, to triiodothyronine, or T3.

This may reveal previously unrecognised central hypothyroidism in people receiving medically supervised growth-hormone treatment.

Specific thyroid effects from CJC-1295 and ipamorelin have not been defined adequately.

Can they affect reproductive hormones?

The growth-hormone system interacts with:

• Testosterone

• Oestrogen

• Insulin

• Thyroid hormones

• Reproductive function

However, CJC-1295 and ipamorelin are not established treatments for:

• Low testosterone

• Infertility

• Menopause

• Low libido

• Erectile dysfunction

Changes in energy or body composition should not be assumed to reflect improved reproductive hormones.

Do they increase testosterone?

There is no reliable evidence that CJC-1295 or ipamorelin directly raises testosterone to a clinically meaningful degree.

Growth hormone and testosterone can have complementary physiological effects, but they are regulated through different endocrine systems.

Do they improve libido?

This has not been established.

Libido is influenced by:

• Sex hormones

• Mental health

• Relationships

• Medication

• Sleep

• Stress

• Physical health

• Body image

Anecdotal changes cannot establish a direct pharmacological effect.

Are CJC-1295 and ipamorelin approved medicines?

No.

Neither compound is authorised in the United Kingdom as a combined treatment for:

• Muscle gain

• Fat loss

• Recovery

• Anti-ageing

• Sleep

• Growth-hormone optimisation

• Injury repair

CJC-1295 underwent early human clinical research, but it did not become an approved routine treatment.

Ipamorelin entered clinical development for postoperative gastrointestinal dysfunction but did not become an established approved treatment for that indication.

There is no authorised combination product with approved prescribing information.

Is the combination clinically proven?

No.

The components have separate bodies of research, but this does not establish the combination.

Evidence supporting one compound cannot automatically prove:

• The ideal ratio

• The optimal exposure

• Greater effectiveness

• Acceptable long-term safety

• Lower risk

• A specific clinical indication

A proper combination trial would need to compare:

• CJC-1295 alone

• Ipamorelin alone

• Both together

• Placebo

• Possibly established treatment

No mature clinical evidence base of this kind exists for commonly promoted uses.

Is CJC-1295 with DAC safer than without DAC?

This has not been established.

The versions create different exposure patterns.

Long-acting DAC form

Potential advantages for research include:

• Less frequent exposure

• Sustained activity

• Stable IGF-1 elevation

Potential concerns include:

• Prolonged effects after an adverse response

• Accumulation

• Sustained elevation between natural GH pulses

• Less control over exposure

Short-acting modified GRF

Potential theoretical characteristics include:

• Briefer receptor stimulation

• More pulse-like exposure

• Faster reduction after discontinuation

Potential concerns include:

• More frequent administration

• Greater dependence on timing

• Limited direct human pharmacokinetic evidence

• Product-name confusion

There is insufficient comparative research to declare one version safer.

What is the half-life of CJC-1295?

For original CJC-1295 with DAC, controlled human research reported an estimated half-life of approximately six to eight days.

Its biological effect on IGF-1 persisted beyond the period of the most obvious growth-hormone elevation.

This estimate should not be applied to “CJC-1295 without DAC.”

Short-acting modified GRF compounds do not possess the same albumin-binding structure and are expected to have a substantially shorter duration.

What is the half-life of ipamorelin?

A definitive, universally accepted human half-life for ipamorelin in the context of growth-hormone enhancement is not well established in accessible peer-reviewed literature.

Precise figures repeated online may be derived from limited pharmacokinetic data, informal sources or particular formulations.

The duration of a growth-hormone pulse is not necessarily identical to the circulating half-life of the peptide.

Can animal doses be converted into human doses?

Not reliably for unsupervised use.

Body-surface-area calculations are sometimes used during drug development, but safe first-in-human exposure also depends on:

• Toxicology

• Pharmacokinetics

• Receptor potency

• Safety margins

• Product quality

• Route

• Monitoring

A numerical animal-to-human conversion does not create an evidence-based therapeutic dose.

Injection-related risks

Injecting an experimental peptide introduces risks separate from the biological activity of the compound.

These include:

• Pain

• Redness

• Swelling

• Bruising

• Cellulitis

• Abscess

• Contamination

• Endotoxin exposure

• Incorrect quantity

• Accidental intravascular administration

• Reconstitution errors

A chemically pure product is not automatically sterile.

Immunogenicity

Externally administered peptides can potentially trigger immune responses.

Risk depends on:

• Sequence

• Aggregation

• Impurities

• Chemical modifications

• Route

• Frequency

• Formulation

• Individual susceptibility

Possible outcomes include:

• Local reactions

• Antibody formation

• Reduced effect

• Altered clearance

• Hypersensitivity

• Cross-reactivity

CJC-1295’s albumin-binding design also creates a peptide-protein conjugate, making regulated safety assessment particularly important.

The early clinical study did not identify major immunogenicity concerns during its limited timeframe, but it was not large or long enough to exclude uncommon or delayed effects.

Product-quality concerns

Products sold outside an authorised medicinal supply chain may contain:

• The wrong peptide

• Incorrect amino-acid sequences

• Incorrect quantities

• Degraded material

• Residual solvents

• Counterions

• Microbial contamination

• Endotoxin

• Undeclared substances

The naming confusion around CJC-1295 creates an additional risk.

A label may not make clear whether it contains:

• True CJC-1295 with DAC

• Modified GRF 1-29

• Another GHRH analogue

• A mixture

• No active peptide

Anti-doping research has developed analytical methods specifically because CJC-1295 and related GHRH analogues require careful chemical identification.

Is a purity result enough?

No.

An HPLC purity result may estimate how much of the detected chromatographic material belongs to the main peak.

It does not necessarily establish:

• Correct identity

• Correct sequence

• Presence of DAC

• Correct net peptide quantity

• Sterility

• Endotoxin control

• Stability

• Human safety

Mass spectrometry and sequence-specific analysis are needed to distinguish closely related GHRH analogues.

Are CJC-1295 and ipamorelin prohibited in sport?

Yes.

The 2026 World Anti-Doping Agency Prohibited List includes growth hormone-releasing factors.

It explicitly covers:

• GHRH and its analogues, including CJC-1295

• Growth hormone secretagogues

• Ghrelin and ghrelin mimetics, including ipamorelin

They are prohibited at all times, both in and out of competition.

Athletes are responsible for any prohibited substance detected in their samples, regardless of why it was used.

Can anti-doping laboratories detect CJC-1295?

Yes.

Analytical methods have been developed to detect CJC-1295 and its characteristic metabolites or peptide fragments.

The DAC form creates an additional analytical challenge because it binds to albumin and other plasma proteins.

Specialised methods can use:

• Immunoaffinity capture

• Enzymatic digestion

• Liquid chromatography

• Tandem mass spectrometry

Research has demonstrated methods for identifying albumin-bound CJC-1295 exposure.

Can ipamorelin be detected?

Growth hormone secretagogues and their metabolites can be targeted using mass-spectrometric anti-doping methods.

The exact detection window varies with:

• Exposure

• Sample type

• Metabolism

• Laboratory sensitivity

• Timing

• Product identity

Online detection estimates should not be treated as reliable guarantees.

Common myths about CJC-1295 and ipamorelin

Myth: CJC-1295 without DAC is the same molecule with a shorter half-life

Fact: The term usually refers to modified GRF 1-29, a structurally different short-acting GHRH analogue.

Myth: Because they stimulate natural growth hormone, the effects are completely physiological

Fact: External compounds can create prolonged or amplified endocrine exposure beyond normal signalling.

Myth: Preserved growth-hormone pulses mean CJC-1295 does not alter baseline hormone levels

Fact: Human research found markedly elevated trough growth hormone and increased mean exposure.

Myth: Ipamorelin affects only growth hormone

Fact: It acts at the ghrelin receptor, which is involved in several physiological systems.

Myth: Ipamorelin never affects hunger, cortisol or prolactin

Fact: It appears more selective than older GHRPs, but absolute absence of these effects has not been established.

Myth: Higher IGF-1 always improves health

Fact: Both deficient and excessive growth-hormone signalling can be harmful.

Myth: Increased lean mass automatically means new muscle

Fact: Fluid and connective-tissue changes can increase measured lean mass.

Myth: The combination has been clinically proven for fat loss

Fact: No mature controlled trial programme establishes this use.

Myth: Growth-hormone stimulation heals tendons

Fact: Mechanistic plausibility is not proof of functional human tendon repair.

Myth: Better sleep is guaranteed because growth hormone normally rises at night

Fact: Hormone release during sleep does not prove that increasing the hormone treats sleep disorders.

Myth: Peptides cannot cause serious adverse effects

Fact: Endocrine disruption, metabolic effects, immune reactions and product-quality risks remain possible.

Myth: Research-use labelling makes the products permitted in sport

Fact: Both substances are prohibited under anti-doping rules.

Frequently asked questions

What is CJC-1295?

CJC-1295 is a long-acting synthetic GHRH analogue designed to bind circulating albumin and stimulate growth-hormone release for several days.

What is ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue that activates the ghrelin receptor.

Are CJC-1295 and ipamorelin the same?

No.

They activate different receptors.

Why are they used together in research?

The GHRH and ghrelin-receptor pathways can work synergistically to stimulate growth-hormone release.

Does the combination have human clinical trials?

There is limited human research on the individual compounds, but no mature clinical-trial programme establishing the commonly promoted combination.

What does CJC stand for?

The name originated from the compound’s pharmaceutical-development programme rather than from a standard physiological abbreviation.

What does DAC mean?

DAC means drug affinity complex.

It allows original CJC-1295 to bind to albumin.

Is CJC-1295 without DAC really CJC-1295?

The name is commonly used commercially, but the compound is usually a short-acting modified GRF 1-29 rather than original DAC-containing CJC-1295.

How many amino acids are in CJC-1295?

CJC-1295 is a modified 30-amino-acid GHRH-related peptide with an additional reactive DAC structure.

How many amino acids are in ipamorelin?

Ipamorelin is a pentapeptide-related growth hormone secretagogue.

Does CJC-1295 increase growth hormone?

Yes.

Controlled human studies demonstrated prolonged increases.

Does CJC-1295 increase IGF-1?

Yes.

Human studies found sustained increases in IGF-1.

Does ipamorelin increase growth hormone?

Yes.

Its principal pharmacological action is stimulation of growth-hormone release through the ghrelin receptor.

Does ipamorelin increase IGF-1?

It may do so indirectly through repeated growth-hormone stimulation, but the magnitude in commonly promoted use is not well established.

Is CJC-1295 growth hormone?

No.

It stimulates the pituitary to release growth hormone.

Is ipamorelin growth hormone?

No.

It is a growth hormone secretagogue.

Is CJC-1295 the same as sermorelin?

No.

Sermorelin is a shorter GHRH-related peptide without CJC-1295’s DAC albumin-binding structure.

Is CJC-1295 the same as tesamorelin?

No.

Tesamorelin is a different GHRH analogue with a specific authorised indication in some jurisdictions.

Is ipamorelin the same as GHRP-6?

No.

Both activate the ghrelin receptor, but they differ in structure and selectivity.

Is ipamorelin the same as ghrelin?

No.

It is a synthetic ghrelin-receptor agonist.

Does ipamorelin make people hungry?

It may influence appetite because it activates the ghrelin receptor, although the effect may be less pronounced than with some older secretagogues.

Does ipamorelin increase cortisol?

It appears less likely to do so than some older GHRPs, but a complete absence of effect has not been established.

Does ipamorelin increase prolactin?

It appears relatively selective, but comprehensive human evidence is limited.

Does the combination build muscle?

Clinically meaningful muscle growth has not been demonstrated in robust controlled trials.

Does it increase strength?

This has not been established.

Does it improve athletic performance?

There is insufficient controlled evidence, and both compounds are prohibited in sport.

Does it reduce body fat?

Substantial human fat loss from the combination has not been proven.

Does it reduce visceral fat?

This remains unproven.

Does it increase metabolism?

Growth-hormone signalling affects metabolism, but a clinically meaningful increase in resting metabolic rate has not been established.

Does it improve recovery?

Broad recovery benefits have not been demonstrated through controlled human trials.

Does it heal tendons?

No reliable clinical evidence establishes tendon healing.

Does it heal ligaments?

No reliable clinical evidence establishes ligament healing.

Does it improve skin quality?

Growth-hormone and IGF-1 signalling can affect skin and connective tissue, but cosmetic benefit from this combination has not been established.

Does it improve collagen production?

Growth-hormone signalling can affect collagen metabolism, but this does not prove improved skin or injury healing.

Does it improve sleep?

Controlled evidence is insufficient.

Does it increase deep sleep?

This has not been established for the combination.

Does it increase energy?

There is no reliable evidence of a predictable stimulant or anti-fatigue effect.

Does it improve libido?

This has not been established.

Does it raise testosterone?

No reliable evidence shows a meaningful direct testosterone increase.

Does it cause water retention?

Potentially, through growth-hormone-related sodium and fluid retention.

Can it cause tingling or numb hands?

Potentially.

Growth-hormone-related fluid changes can contribute to nerve-compression symptoms.

Can it cause headaches?

Possibly, although the true incidence is unknown.

Can it increase blood glucose?

Potentially.

Growth hormone can reduce insulin sensitivity.

Can it cause diabetes?

The long-term diabetes risk from the combination is unknown.

Sustained growth-hormone excess can impair glucose regulation.

Can it affect blood pressure?

Potentially, through fluid balance and cardiovascular signalling.

Can it cause heart enlargement?

This has not been demonstrated directly for ordinary experimental exposure, but chronic growth-hormone excess can affect the heart.

Can it cause cancer?

It has not been proven to cause human cancer.

Long-term safety around growth-related pathways remains insufficiently studied.

Is it safe after cancer?

Safety in people with current or previous cancer has not been established.

Can it enlarge organs?

Long-term effects on organ growth have not been defined adequately.

Can it affect sleep apnoea?

Potential worsening is biologically plausible in susceptible individuals because of fluid and soft-tissue effects.

Can it affect the thyroid?

Growth-hormone signalling can alter thyroid-hormone metabolism.

Specific effects from the combination remain inadequately defined.

Can it interact with diabetes medication?

Potentially, because it may change glucose regulation.

Formal interaction studies are lacking.

Can it interact with growth hormone?

Combining multiple growth-hormone-promoting agents could increase endocrine exposure and adverse effects.

Is CJC-1295 approved in the UK?

No.

Is ipamorelin approved in the UK?

No.

Is the combination approved anywhere for anti-ageing?

There is no recognised authorised anti-ageing indication.

Is CJC-1295 clinically proven?

Its ability to increase growth hormone and IGF-1 is demonstrated.

Clinical benefit for commonly promoted uses is not.

Is ipamorelin clinically proven?

It has pharmacological and limited clinical research, but it is not an established muscle, fat-loss or anti-ageing treatment.

What is CJC-1295’s half-life?

For the original DAC-containing compound, human research estimated a half-life of approximately six to eight days.

Does that half-life apply to CJC-1295 without DAC?

No.

What is ipamorelin’s half-life?

A definitive human value applicable to informal growth-hormone use is not firmly established in the published evidence.

Is there an approved human dose?

No approved combination dose exists.

Can animal doses be converted to human doses?

A mathematical conversion does not establish safe use.

Are they prohibited in sport?

Yes.

Both are prohibited at all times.

Can CJC-1295 be detected in anti-doping tests?

Yes.

Specific analytical methods have been developed.

Can ipamorelin be detected?

Yes, relevant growth hormone secretagogues and metabolites can be targeted.

Is oral CJC-1295 effective?

Reliable oral bioavailability has not been established.

Is oral ipamorelin effective?

Ipamorelin was generally developed for non-oral administration, and reliable oral effectiveness has not been established.

Can either compound cause an immune reaction?

Potentially.

Peptides, conjugates, aggregates and impurities can trigger immune responses.

Does purity prove safety?

No.

Purity does not establish correct identity, quantity, sterility, endotoxin control or long-term clinical safety.

Research in context

What do we know with reasonable confidence?

• Growth hormone is secreted in pulses from the pituitary.

• GHRH and ghrelin-receptor signalling regulate growth-hormone release through different pathways.

• CJC-1295 is a modified GHRH analogue.

• Original CJC-1295 contains a DAC structure that binds albumin.

• Human studies show that CJC-1295 increases growth hormone and IGF-1 for several days.

• Growth-hormone pulsatility can remain present while baseline concentrations rise.

• Ipamorelin is a ghrelin-receptor agonist and growth hormone secretagogue.

• Early research suggests ipamorelin is more selective for growth-hormone release than some older GHRPs.

• Ipamorelin has entered human gastrointestinal clinical research.

• Neither compound is an authorised UK anti-ageing or performance medicine.

• Both are prohibited in regulated sport.

What remains uncertain?

• Long-term combination safety

• The ideal exposure for any medical condition

• Effects on meaningful muscle strength

• Effects on athletic recovery

• Effects on body fat

• Long-term glucose and diabetes risk

• Cardiovascular outcomes

• Cancer-related safety

• Reproductive safety

• Interaction with other hormones or medicines

• Immunogenicity after prolonged use

• Whether short-acting modified GRF has advantages over DAC-containing CJC-1295

• Whether commonly sold products contain the labelled compound

What should readers be cautious about?

• Treating “CJC-1295 with DAC” and “without DAC” as identical

• Claims that natural pituitary release guarantees safety

• Assuming higher IGF-1 is always beneficial

• Equating increased lean mass with contractile muscle

• Fat-loss claims unsupported by controlled imaging studies

• Injury-healing claims based only on growth-factor biology

• Claims of guaranteed deep sleep

• Claims that ipamorelin has no appetite or endocrine effects

• Precise dosing claims without authorised guidance

• Precise ipamorelin half-life claims without a traceable human source

• Ignoring glucose and fluid-retention risks

• Assuming a purity certificate proves identity or sterility

• Ignoring anti-doping restrictions

Key takeaways

CJC-1295 and ipamorelin are experimental growth hormone secretagogues that act through different receptors.

CJC-1295 is a modified growth hormone-releasing hormone analogue.

Original CJC-1295 contains a drug affinity complex that binds circulating albumin and produces prolonged biological activity.

Human trials found that it increased growth hormone for several days and IGF-1 for longer.

Ipamorelin activates the ghrelin receptor and stimulates growth-hormone release through a separate pathway.

It was developed as a relatively selective secretagogue with less ACTH and cortisol stimulation than some older GHRPs in early experimental research.

Combining GHRH and ghrelin-receptor stimulation can plausibly produce a larger growth-hormone response.

However, biological synergy does not establish clinical benefit or safety.

There are no large controlled trials showing that the CJC-1295 and ipamorelin combination reliably:

• Builds functional muscle

• Reduces body fat

• Improves athletic performance

• Repairs tendons or ligaments

• Improves sleep

• Reverses ageing

Potential concerns include:

• Elevated IGF-1

• Fluid retention

• Nerve-compression symptoms

• Headaches

• Altered blood glucose

• Reduced insulin sensitivity

• Cardiovascular effects

• Growth-related tissue effects

• Immune reactions

• Product contamination

“CJC-1295 without DAC” usually refers to a different short-acting GHRH analogue and should not be confused with the original albumin-binding molecule investigated in human trials.

Neither CJC-1295 nor ipamorelin is an authorised UK medicine for body composition, recovery or anti-ageing.

Both are prohibited in regulated sport.

The scientifically accurate conclusion is that the compounds can stimulate the human growth-hormone axis, but evidence showing meaningful long-term health, performance or body-composition benefits remains inadequate.

Glossary

Acromegaly: A disorder caused by chronic excessive growth-hormone and IGF-1 activity in adults.

ACTH: Adrenocorticotropic hormone, which stimulates cortisol production.

Albumin: A major circulating blood protein that transports many molecules.

Anterior pituitary: The front portion of the pituitary gland, where growth hormone is produced.

CJC-1295: A long-acting modified GHRH analogue containing an albumin-binding drug affinity complex.

DAC: Drug affinity complex, the chemical structure enabling CJC-1295 to bind albumin.

Dipeptidyl peptidase-4: An enzyme that breaks down several peptides, including natural GHRH.

Endogenous: Produced naturally within the body.

Ghrelin: A stomach-derived hormone involved in appetite, gastrointestinal function and growth-hormone release.

GHRH: Growth hormone-releasing hormone.

GHRH receptor: The pituitary receptor activated by GHRH and related analogues.

GHRP: Growth hormone-releasing peptide.

GHS-R1a: The classical ghrelin receptor through which ipamorelin stimulates growth-hormone release.

Growth hormone: A pituitary hormone involved in growth, metabolism and tissue regulation.

Growth hormone secretagogue: A substance that stimulates the release of growth hormone.

Half-life: The time required for the concentration of a substance to fall by half.

Hypothalamus: A brain region that controls many endocrine and physiological functions.

IGF-1: Insulin-like growth factor 1, produced mainly by the liver in response to growth hormone.

Ipamorelin: A synthetic ghrelin-receptor agonist and growth hormone secretagogue.

Lean body mass: Body mass excluding fat, including muscle, water, organs and connective tissue.

Lipolysis: Breakdown of stored fat to release fatty acids.

Modified GRF 1-29: A short-acting modified GHRH analogue often marketed as CJC-1295 without DAC.

Pentapeptide: A peptide containing five amino-acid units.

Pharmacodynamics: The study of what a substance does to the body.

Pharmacokinetics: The study of absorption, distribution, metabolism and elimination.

Prolactin: A pituitary hormone involved mainly in lactation and reproductive physiology.

Pulsatile secretion: Hormone release occurring in intermittent peaks rather than continuously.

Somatostatin: A hormone that inhibits growth-hormone release.

Somatotroph: A pituitary cell that produces and releases growth hormone.

Synergy: An effect produced by two substances that is greater than the expected sum of their separate effects.

Tachyphylaxis: Rapid reduction in response after repeated exposure.

Important notice

This article is provided for general scientific and educational purposes.

It is not intended to diagnose, treat or prevent any medical condition. It should not be interpreted as medical advice, prescribing guidance, hormone-replacement guidance, performance-enhancement guidance or instructions for administering CJC-1295 or ipamorelin.

CJC-1295 with DAC and products marketed as “CJC-1295 without DAC” are not pharmacologically identical compounds.

Human evidence confirms that CJC-1295 can increase growth hormone and IGF-1. It does not establish the claimed benefits of combining CJC-1295 with ipamorelin for muscle growth, fat loss, recovery, sleep or anti-ageing.

Neither compound is an authorised UK medicine for these purposes, and both are prohibited under current World Anti-Doping Agency rules.